AMARIN CORP PLC -ADR (AMRN) Stock Price, Quote, News and Overview
NASDAQ:AMRN - Nasdaq - US0231114044 - ADR - Currency: USD
AMRN Quote, Performance and Key Statistics
10.27
-0.15 (-1.44%)
The current stock price of AMRN is 10.27 USD. In the past month the price increased by 8.45%. In the past year, price decreased by -40.98%.
AMRN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.57B | ||
| AMGN | AMGEN INC | 13.03 | 145.41B | ||
| GILD | GILEAD SCIENCES INC | 13.1 | 126.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.96 | 61.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.71B | ||
| ARGX | ARGENX SE - ADR | 92.41 | 33.12B | ||
| ONC | BEIGENE LTD-ADR | 5.58 | 24.22B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.72B | ||
| NTRA | NATERA INC | N/A | 20.70B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.28B | ||
| BIIB | BIOGEN INC | 7.79 | 18.05B |
Related stock screener links
About AMRN
Company Profile
Amarin Corporation PLC is a IE-based company operating in Biotechnology industry. Amarin Corporation PLC is a pharmaceutical company. The firm is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The firm operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Company Info
AMARIN CORP PLC -ADR
First Floor, Block 3, The Oval,, Shelbourne Road, Ballsbridge
DUBLIN Dublin 2 IE
CEO: John F. Thero
Employees: 275
Phone: 35316699020
AMARIN CORP PLC -ADR / AMRN FAQ
What is the stock price of AMARIN CORP PLC -ADR today?
The current stock price of AMRN is 10.27 USD. The price decreased by -1.44% in the last trading session.
What is the ticker symbol for AMARIN CORP PLC -ADR stock?
The exchange symbol of AMARIN CORP PLC -ADR is AMRN and it is listed on the Nasdaq exchange.
On which exchange is AMRN stock listed?
AMRN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AMARIN CORP PLC -ADR stock?
8 analysts have analysed AMRN and the average price target is 13.77 USD. This implies a price increase of 34.08% is expected in the next year compared to the current price of 10.27. Check the AMARIN CORP PLC -ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AMARIN CORP PLC -ADR worth?
AMARIN CORP PLC -ADR (AMRN) has a market capitalization of 4.25B USD. This makes AMRN a Mid Cap stock.
How many employees does AMARIN CORP PLC -ADR have?
AMARIN CORP PLC -ADR (AMRN) currently has 275 employees.
What are the support and resistance levels for AMARIN CORP PLC -ADR (AMRN) stock?
AMARIN CORP PLC -ADR (AMRN) has a support level at 10.26 and a resistance level at 10.87. Check the full technical report for a detailed analysis of AMRN support and resistance levels.
Is AMARIN CORP PLC -ADR (AMRN) expected to grow?
The Revenue of AMARIN CORP PLC -ADR (AMRN) is expected to decline by -8.24% in the next year. Check the estimates tab for more information on the AMRN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AMARIN CORP PLC -ADR (AMRN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AMRN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AMRN, evaluating the profitability, health, valuation and growth aspects
- AMARIN CORP PLC -ADR (AMRN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AMARIN CORP PLC -ADR (AMRN) Sales and EPS estimates to see what analysts future expectations are.
- AMARIN CORP PLC -ADR (AMRN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AMARIN CORP PLC -ADR (AMRN) Insider and Institutional Ownership to learn about the owners and their transactions.
- AMARIN CORP PLC -ADR (AMRN) Stock Chart to make your own analysis
- AMARIN CORP PLC -ADR (AMRN) Latest news and press-releases to stay up to date.
Does AMARIN CORP PLC -ADR (AMRN) stock pay dividends?
AMRN does not pay a dividend.
What is the Price/Earnings (PE) ratio of AMARIN CORP PLC -ADR (AMRN)?
AMARIN CORP PLC -ADR (AMRN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.84).
AMRN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to AMRN. When comparing the yearly performance of all stocks, AMRN is a bad performer in the overall market: 85.55% of all stocks are doing better.
AMRN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AMRN. AMRN has a great financial health rating, but its profitability evaluates not so good.
AMRN Financial Highlights
Over the last trailing twelve months AMRN reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS increased by 23.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.99% | ||
| ROE | -16.9% | ||
| Debt/Equity | 0 |
AMRN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to AMRN. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -43.26% and a revenue growth -8.24% for AMRN